Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy

NCT00917813 is registered in ClinicalTrials.gov with The Chemo-Sero-Therapeutic Research Institute as lead sponsor.

NCT NCT00917813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00917813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Lead sponsor
The Chemo-Sero-Therapeutic Research Institute
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2007
Completion date
Not reported
Enrollment
27 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections